Sarepta’s Elevidys Sales Surge, But Next-Gen DMD Drug Platform Discontinued

Safety Scuttles SRP-5051, All Other PPMO Assets

 
• By Mandy Jackson
  
The rise in Elevidys sales did not push other Sarepta product sales down in Q3 (Shutterstock)

More from Earnings

More from Scrip